Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22393723 | 1.00 | CYP2D6 (0.36) | CYP2D6PTPN11 | |
| SCHEMBL21845245 | 0.84 | PTPN11 (0.34) | PTPN11 | |
| SCHEMBL21887296 | 0.81 | GRIN2D (0.37) | PTPN11 | |
| SCHEMBL24089033 | 0.81 | GRIN2D (0.37) | PTPN11 | |
| SCHEMBL21887245 | 0.81 | PTPN11 (0.46) | CYP2D6PTPN11 | |
| SCHEMBL22393722 | 0.80 | CYP2D6 (0.40) | CYP2D6PTPN11 | |
| SCHEMBL21887248 | 0.80 | CYP2D6 (0.40) | CYP2D6PTPN11 | |
| SCHEMBL21887244 | 0.75 | CYP2D6 (0.38) | CYP2D6PTPN11 | |
| SCHEMBL21845230 | 0.72 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL22393785 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | CYP2D6 4469/4885PTPN11 32/4885 |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | CYP2D6 4469/4885PTPN11 32/4885 |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | CYP2D6 4506/4885PTPN11 27/4885 |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | CYP2D6 4469/4885PTPN11 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.